On February 2, 2018 Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported that it will host a conference call and webcast on Wednesday, February 7, 2018 at 8:00 a.m. ET to discuss its fourth quarter and full year 2017 financial results (Press release, Keryx Biopharmaceuticals, FEB 2, 2018, https://keryx.gcs-web.com/news-releases/news-release-details/keryx-biopharmaceuticals-host-conference-call-fourth-quarter-1 [SID1234523749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 3697815. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.

Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.

On February 2, 2018 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it will host a webcast and conference call on Friday, February 9, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal 2018 first quarter ended December 31, 2017 (Press release, Arrowhead Pharmaceuticals, FEB 2, 2018, View Source [SID1234523702]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company’s website at View Source For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 4788374.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 4788374.

On February 2, 2018 bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, reported that members of the management team will present at the LEERINK Partners 7th Annual Global Healthcare Conference, Wednesday, February 14, at 3:00 p.m. ET at the Lotte New York Palace, New York City (Press release, bluebird bio, FEB 2, 2018, View Source [SID1234523707]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of bluebird bio’s presentation, please visit the "Events & Presentations" page within the Investors and Media section of the bluebird bio website at View Source A replay of the webcast will be available on the bluebird bio website for 90 days following the conference.

On February 2, 2018 Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reported that fourth quarter and full year 2017 financial results will be released on Thursday, February 8, 2018 before the market opens (Press release, Cambrex, FEB 2, 2018, View Source [SID1234523708]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will host a conference call to discuss the financial results.

Fourth Quarter 2017 Earnings Conference Call
When: Thursday, February 8, 2018 at 8:30 a.m. Eastern Time
Dial-in: 1-888- 394-8218 for U.S.
1-323- 701-0226 for International
Passcode: 9709552
Dial-in Replay: 1-888- 203-1112 for U.S.
1-719- 457-0820 for International
Passcode: 9709552
Available through Thursday, February 15, 2018
Webcast: www.cambrex.com

On February 2, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported that it will present an abstract relating to the mechanism of action of rigosertib in combination with azacitidine at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on "Targeting DNA Methylation and Chromatin for Cancer Therapy". The conference is being held in Atlanta, Georgia, on March 1-4, 2018 at the Sheraton Atlanta Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentation are listed below.

Title: Rigosertib (RIG) Alone or in Combination with Azacitidine or Vorinostat has Chromatin Modifying Effects and Epigenetically Reprograms Hematopoietic Stem and Progenitor Cells in the Myelodysplastic Syndrome

Date: Friday, March 2, 2018

Presenter: Dr. Lewis Silverman, Mount Sinai School of Medicine